Volume 4,Issue 5
江北区老年人群新发非瓣膜性房颤筛查及抗凝现状
目的：调查重庆市江北区老年人新发非瓣膜性心房颤动的现状，同时调查非瓣膜性心房颤动人群的抗凝现状。方法：选择在重庆市江北区的老年人（≥65岁，无房颤病史和房颤心律）,采用单导联心电记录仪对研究对象进行十二导联心电图检查，了解社区老年人体检为非瓣膜性心房颤动的检出率，并分析心房颤动与非心房颤动患者的基本特征。采用CHA2DS2-VASc评分及HAS-BLED评分对非瓣膜性心房颤动患者进行评估，随访3个月、半年、1年了解抗凝药物的使用情况。结果：重庆市江北区社区≥65岁的老年人群中新发房颤的检出率为1.1%，其中非瓣膜性房颤检出率为1.0%。在非瓣膜性房颤中使用抗凝药物占62.5%（华法林20%，新型口服抗凝药物80%），使用抗血小板聚集药物占6.25%，未服用抗凝药物占31.25%。
[1] 陈灏珠, 林果为, 王吉耀. 实用内科学[M]. 北京: 人民卫生出版社,2014:1386-138.
[2]CHUGH S S,HAVMOELLER R,NARAYANAN K,et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study[J].Circulation, 2014,129(8):837-847. DOI:10.1161/CIRCULATIONAHA.113.005119.
[3] 冯书梅. 心脏瓣膜置换术后抗凝治疗的监测与护理[J]. 中国实用期刊,2012,39(4):83-84. DOI:10.3760/cma.j.issn.1674-4756.2012.04.045.
[4] 张澍, 杨艳敏, 黄从新, 等. 中国心房颤动患者卒中预防规范(2017)[J]. 中华心律失常学杂志,2018,22(1):17-30. DOI:10.3760/cma.j.issn.1007-6638.2015.03.002.
[5]BEKWELEM W,CONNOLLY S J,HALPERIN J L,et al. Extracranial systemic embolic events in patients with nonvalvular atrialfibrillation:incidence,risk factors,and outcomes[J]. Circulation,2015,132(9):796-803. DOI:10.1016/j.jvs.2016.02.005.
[6]SHI S,TANG Y,ZHAO Q,et al． Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study [J/OL]． Lancet Ｒ eg Health West Pac,2022,23: 100439． DOI: 10． 1016 /j． lanwpc． 2022.100439．
[7]PＲ OIETTI M,Ｒ OMITI G F, Ｒ APAＲ ELLI V,et al． Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1187000 patients [J/OL]． Ageing Ｒ es Ｒ ev,2022,79: 101652． DOI: 10． 1016 /j． arr． 2022． 101652．
[8] 邹晓, 范利．老年心血管疾病与衰弱相关性及研究进展 [J]．中国临床保健杂志,2023,26( 1) : 7-12．
[9]CHEN M, LI C, LIAO P, et al. Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: A medical insurance database study [ J]. Lancet Reg Health West Pac, 2022, 23: 100470. DOI: 10. 1016 / j. lanwpc. 2022. 100470
[10]SVENNBERG E, FRIBERG L, FRYKMAN V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP):A multicentre, parallel group, unmasked, randomised ontrolled trial[ J]. Lancet, 2021, 398(10310):1498-1506.=-8
[11] 董艳, 李小荣, 周秀娟, 等. 心房颤动抗凝治疗的指南更新和实践运用[ J]. 中国心脏起搏与心电生理杂志,2019,33(2): 95 - 99.
[12]KIRCHHOF P, BENUSSI S, KOTECHA D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016,37(38):2893-2962.
[13] 戚天宇, 张晓晖. 非瓣膜性心房颤动合并缺血性脑卒中的药物防治进展[J].疾病监测与控制,2025,19(01):77-81.DOI:10.19891/j.issn1673-9388.(2025)01-0077-05
[14] 汪蓉, 郑春美, 武桂林, 等. 基层医院房颤患者抗凝治疗现状调查研究[J].中国卫生标准管理,2023,14(13):84-88.
[15]DU X, GUO L, XIA S, et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China[J] . Heart, 2021, 107(7): 535 - 541.
[16]HINDRICKS G, POTPARA T, DAGRES N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery ( EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology ( ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[ J]. Eur Heart J, 2021, 42(5): 373 - 498.